Board Meeting Details

The Board of Directors meeting was held on Wednesday, November 11, 2026 at 12:00 Noon at the registered office of the Company. The meeting concluded at 02:00 P.M.

Key Decisions Approved

1. Unaudited Financial Results: Approved standalone and consolidated financial results for the quarter and half year ended September 30, 2026.

2. Limited Review Reports: Approved limited review reports for the quarter and half year ended September 30, 2026.

3. Resignation: Accepted resignation of Mr. Krishna Sainadh Kodati as Company Secretary and Compliance Officer pursuant to his resignation letter dated November 11, 2026, effective November 16, 2026.

4. Appointment: Appointed Mr. Ashok Babu Yaramaneni as Company Secretary and Compliance Officer effective November 16, 2026.

Management Change Details (Annexure I)

Mr. Krishna Sainadh Kodati (Resigning)

  • Reason: Resignation
  • Date of resignation letter: November 11, 2026
  • Relieving effective: November 16, 2026

Mr. Ashok Babu Yaramaneni (Appointed)

  • Date of appointment: November 16, 2026
  • Profile: Qualified Company Secretary with over 18 years of experience in corporate governance, secretarial functions, compliance, regulatory matters particularly in listed companies. Expertise in Companies Act, SEBI Regulations, investor relations, corporate mergers, takeovers, and capital market transactions. Member of ICSI with additional certifications in Securities and Financial Markets Laws.
  • No relationships between directors disclosed (not applicable for company secretary appointment)

Financial Results Overview

Standalone Financials (Amount in ₹ lakhs)

Income Statement - Quarter Ended September 30, 2026:

  • Revenue from operations: ₹2,082.08
  • Total income: ₹2,082.08
  • Total expenses: ₹1,766.57
  • Profit before tax: ₹315.51
  • Total tax expense: ₹143.11
  • Profit after tax: ₹172.40

Income Statement - Half Year Ended September 30, 2026:

  • Revenue from operations: ₹3,780.55
  • Total income: ₹3,780.55
  • Total expenses: ₹3,185.67
  • Profit before tax: ₹594.88
  • Total tax expense: ₹266.56
  • Profit after tax: ₹328.32

Balance Sheet as at September 30, 2026:

  • Total assets: ₹11,406.62
  • Equity share capital: ₹2,008.02
  • Other equity: ₹5,871.60
  • Total equity: ₹7,879.62
  • Total liabilities: ₹3,527.00

Cash Flows - Half Year Ended September 30, 2026:

  • Net cash from operating activities: ₹1,277.39
  • Net cash used in investing activities: ₹(1,388.95)
  • Net cash from financing activities: ₹533.73
  • Net increase in cash: ₹422.17
  • Cash at beginning: ₹946.79
  • Cash at end: ₹1,368.95

Consolidated Financials (Amount in ₹ lakhs)

Income Statement - Quarter Ended September 30, 2026:

  • Revenue from operations: ₹2,082.08
  • Profit before tax: ₹315.51
  • Profit after tax: ₹172.40
  • Comprehensive income: ₹172.40

Income Statement - Half Year Ended September 30, 2026:

  • Revenue from operations: ₹3,780.55
  • Profit before tax: ₹594.88
  • Profit after tax: ₹328.32
  • Comprehensive income: ₹328.32

Balance Sheet as at September 30, 2026:

  • Total assets: ₹12,283.70
  • Equity share capital: ₹2,008.02
  • Other equity: ₹5,683.89
  • Non-controlling interest: ₹65.79
  • Total equity: ₹7,757.70
  • Total liabilities: ₹4,526.00

Subsidiary and Associate Information

The consolidated financial results include:

1. Nayas Laboratories Private Limited (Subsidiary, 59.26% holding)

  • Total assets: ₹1,751.09 lakhs as at September 30, 2026
  • Q2 FY27: Revenue ₹230.95 lakhs, Net profit ₹15.15 lakhs
  • H1 FY27: Revenue ₹368.15 lakhs, Net loss ₹(85.79) lakhs

2. Naya Pharma Private Limited (Associate, 31.03% holding)

  • Q2 FY27: Group's share of net loss ₹0.65 lakhs
  • H1 FY27: Group's share of net loss ₹1.34 lakhs

Additional Financial Information

  • Employee benefit expenses for Q2 FY27 include ₹59.43 lakhs towards ESOP Scheme 2016 provided as per Ind AS 102
  • The company operates in one reportable business segment: Clinical Research Services
  • Segment reporting as per Ind AS 108 is not applicable
  • Financial results prepared in accordance with Ind AS and SEBI regulations

Auditor Review Reports

Standalone Financial Results:

  • Independent auditor: Pavuluri & Co (FRN: 0121948)
  • Review conducted under SRE 2410
  • No material misstatements found
  • Unmodified review report dated November 11, 2026

Consolidated Financial Results:

  • Includes subsidiary (Nayas Laboratories) and associate (Naya Pharma)
  • Subsidiary financials reviewed by auditors
  • Associate financials certified by management (not reviewed by auditors)
  • No material misstatements found
  • Unmodified review report dated November 11, 2026